How India Exports Mebendazole to the World

In the United States, mebendazole is approved for the treatment of various parasitic infections. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for mebendazole, indicating a competitive generic market. Notably, on November 22, 2022, the FDA granted orphan drug designation to mebendazole for the treatment of autosomal dominant polycystic kidney disease, as per the FDA's Orphan Drug Designations and Approvals database. This designation provides incentives for the development of drugs for rare diseases.

Regarding import alerts, as of March 2026, there are no specific FDA import alerts related to mebendazole. However, the FDA maintains general import alerts for various countries and products, which are subject to change based on compliance and safety concerns. Exporters should regularly consult the FDA's Import Alert database to ensure compliance with current regulations.

In the European Union, mebendazole is authorized for use in treating parasitic infections. The European Medicines Agency (EMA) maintains a list of nationally authorized medicinal products containing mebendazole, as detailed in their document published on January 15, 2026. This list provides comprehensive information on the marketing authorizations granted by individual EU member states.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization of medicinal products, including mebendazole. Manufacturers and exporters must comply with the UK's regulatory requirements, which include obtaining marketing authorization and adhering to Good Manufacturing Practice (GMP) standards.

Mebendazole is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in treating parasitic infections globally. The WHO's Prequalification Programme ensures that medicines meet global standards of quality, safety, and efficacy. Additionally, mebendazole is recognized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), reflecting its widespread acceptance and standardized quality parameters.

In India, mebendazole is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription drug requiring a doctor's prescription for dispensation. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, mebendazole is not listed under the Drugs (Prices Control) Order (DPCO), implying no ceiling price is currently imposed. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products. Exporters should verify the latest DGFT notifications to determine if mebendazole requires an export NOC.

Mebendazole's primary patents have expired, allowing for the production and marketing of generic versions. The presence of multiple approved ANDAs in the FDA's Orange Book indicates a competitive generic market. The orphan drug designation granted in November 2022 for a new indication (autosomal dominant polycystic kidney disease) may provide market exclusivity for that specific use upon approval.

In December 2022, the European Medicines Agency (EMA) granted orphan designation to mebendazole for the treatment of autosomal dominant polycystic kidney disease, as per the EMA's official records. This designation aims to encourage the development of drugs for rare diseases by providing incentives such as market exclusivity.

In January 2026, the EMA published a comprehensive list of nationally authorized medicinal products containing mebendazole, providing updated information on its regulatory status across EU member states. This publication serves as a valuable resource for stakeholders seeking detailed information on mebendazole's approval status within the EU.

These developments highlight the ongoing regulatory activities and the potential expansion of mebendazole's therapeutic applications beyond its traditional use as an anthelmintic.

Mebendazole, an anthelmintic medication, is primarily produced in India, which has established itself as a significant hub for Active Pharmaceutical Ingredient (API) manufacturing. However, the production of APIs like mebendazole is heavily reliant on Key Starting Materials (KSMs), many of which are imported from China. This dependency poses a substantial risk, as any disruption in the supply of KSMs can halt API production. According to the U.S. Pharmacopeia, 58% of KSMs used for U.S.-approved APIs are sourced from a single country, with 41% from China and 16% from India.

Recent geopolitical tensions have exacerbated this vulnerability. In February 2026, the escalation of the U.S.-Iran conflict led to significant disruptions in the Strait of Hormuz, a critical maritime corridor for global trade. These disruptions have affected the transportation of raw materials, including KSMs, thereby impacting API production timelines and costs.

Our proprietary trade data indicates that the top five Indian exporters of mebendazole account for 54.5% of total exports, with KROSYL PHARMACEUTICALS PRIVATE LIMITED leading at 19.7%. This concentration suggests a moderate risk, as reliance on a limited number of suppliers can lead to supply chain disruptions if any of these entities face operational challenges.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of critical APIs and reduce dependence on imports. In November 2024, two greenfield plants were inaugurated under this scheme to produce essential molecules for antibiotics, marking a significant step toward self-reliance in pharmaceutical manufacturing.

The recent military escalation in the Middle East, particularly around the Strait of Hormuz and the Red Sea, has led to heightened security risks and shipping disruptions. Major shipping lines have suspended transits through these critical waterways, resulting in longer transit times and increased freight costs. For instance, Europe-bound shipments from India are now taking the longer route around the Cape of Good Hope, extending transit times by 10–20 days and raising freight rates by 40–50%.

These disruptions have a cascading effect on the pharmaceutical supply chain, potentially leading to delays in the delivery of mebendazole to international markets. While there have been no specific shortage alerts from regulatory bodies like the FDA or EMA as of March 2026, the situation remains fluid, and stakeholders should stay vigilant to any emerging notifications.

• Diversify Supplier Base: Engage with a broader range of KSM and API suppliers to reduce dependency on a limited number of sources.

• Enhance Domestic Production: Leverage government initiatives like the PLI scheme to bolster domestic manufacturing capabilities for critical APIs and KSMs.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on supply chains.

• Develop Contingency Plans: Create and regularly update contingency plans to address potential disruptions in raw material supply and shipping routes.

• Strengthen Supplier Relationships: Foster strong partnerships with existing suppliers to ensure priority access to materials during periods of high demand or disruption.

RISK_LEVEL: MEDIUM